MedTrace Logo

Improve Muscle Weakness in Patient With COPD

NCT07649850 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-06-16

No results posted yet for this study

Summary

This randomized controlled trial investigated the effects of combining aerobic exercise with blood flow restriction (BFR) training in patients with emphysematous chronic obstructive pulmonary disease (COPD). The study aimed to determine whether adding BFR to aerobic exercise could enhance muscle strength and functional capacity compared with conventional training alone. The findings demonstrated that aerobic exercise combined with BFR significantly improved lower-limb muscle strength, exercise tolerance, and functional performance in patients with emphysematous COPD. These results suggest that BFR-assisted aerobic training may serve as an effective and safe rehabilitation strategy to improve physical function and quality of life in this population.

Conditions

  • Emphysema or COPD

Interventions

OTHER

Aerobic Exercise Combined with Blood Flow Restriction

Aerobic exercise combined with blood flow restriction (BFR) is a rehabilitation technique in which patients perform low- to moderate-intensity aerobic exercise, such as treadmill or cycling training, while a specialized cuff is applied around the proximal part of the limb to partially restrict blood flow. This method aims to enhance muscle strength and functional performance using lower exercise intensity, making it suitable for patients with limited exercise tolerance, such as individuals with COPD.

OTHER

Aerobic exercise

The control group performed conventional aerobic exercise training at low to moderate intensity without the application of blood flow restriction. The program included activities such as treadmill walking or cycling to improve cardiovascular endurance, functional capacity, and overall physical fitness in patients with COPD.

Sponsors & Collaborators

  • Al-Zaytoonah University of Jordan

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-10
Primary Completion
2026-08-15
Completion
2026-08-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07649850 on ClinicalTrials.gov